Polyrizon

Polyrizon is a biotech company focused on the development and commercialization of innovative intranasal products. Polyrizons Capture & Contain (C&C) platform is based on a natural 3D polymeric network tailored to optimally adhere to the nasal mucosal surface. The polymeric network creates a physical barrier that captures and contains biological contaminants, preventing their penetration. The C&C platform can be readily adapted for a wide range of applications to protect the human body from airborne contaminants such as allergens, viruses, and molds. The companys Trap & Target (T&T) platform delivery technology is designed to allow a long residence time and intimate contact with the mucosal tissue for highly effective targeted delivery of medicines. It can be tailored to address the specific requirements of different molecules for improved therapeutic effect.

Polyrizon has raised $23.53M in total funding across 8 rounds. The company is currently at the Public stage. Key investors include srugo Reuven construction co. ltd., Xylo Technologies.

Polyrizon was founded in 2020 by Tomer Izraeli (Founder & CEO).

Polyrizon operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery. Target customers: Healthcare & Life Sciences, Medical Devices Industry, Medical Products, Healthcare, Providers, Patients, Life Sciences, Pharmaceuticals.

Polyrizon is based in HaTidhar St 5, Ra'anana, Israel, Center District.